-
April 2026: This Month in Huntington’s Disease Research
Latest News
-
Building a Better Mouse(trap): A New Model of Huntington’s Disease
New mouse model gives insights into Huntington's disease
-
Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
HD causes the normally helpful protein "ATM" to get a little overzealous. Now we can look for drugs to settle it down
-
2015 Huntington's Disease Therapeutics Conference: Day 3
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 2
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-
2015 Huntington's Disease Therapeutics Conference: Day 1
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
-
Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
Antibodies are known for their role in immunity, but researchers repurpose them in many ways. Can they be used in HD?
-
Drug Improves Huntington’s Symptoms in Mice – and Their Offspring
HD drug changes DNA folding across generations
-
mTORC1 tips the scales in Huntington’s disease mice
Weighing the scales on mTORC1: A possible new target for HD therapeutics?
-
Can this synthetic oil help feed the brain in Huntington's disease?
A new study shows a synthetic oil called triheptanoin changes how HD brains use energy. But will it help HD?
-
Positive results announced for re-worked tetrabenazine drug in Huntington's disease
Modified 'heavy hydrogen' form of tetrabenazine appears safe and effective for chorea in Huntington's disease
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
